Respiratory Medicine Case Reports (Jan 2024)

First-line selpercatinib for a patient with RET fusion-positive pulmonary large cell neuroendocrine carcinoma

  • Tatsuru Eihuku,
  • Seiichi Miwa,
  • Tomoko Oshima,
  • Hisano Ohba,
  • Masahiro Shirai

Journal volume & issue
Vol. 52
p. 102116

Abstract

Read online

Pulmonary large cell neuroendocrine carcinoma (LCNEC) is an uncommon variant of non-small cell lung cancer (NSCLC), known for its aggressive behavior. This includes rapid progression, widespread metastases, and resistance to conventional chemotherapy, all of which contribute to a dismal prognosis. Consequently, managing pulmonary LCNEC remains a significant challenge. In this case report, we describe the successful use of selpercatinib, RET (rearranged during transfection) kinase inhibitor, as a first-line treatment in a patient with advanced pulmonary LCNEC harboring a RET fusion gene. Although RET fusion genes are exceedingly rare in pulmonary LCNEC, this case underscores the importance of early genetic testing in patients with pulmonary LCNEC to tailor targeted therapies effectively.

Keywords